Precision medicine for advanced biliary tract cancer in China: current status and future perspectives

Abstract

Biliary tract cancer (BTC) is a rare group of malignancies that develop from the epithelial lining of the biliary tree and have a poor prognosis. Although chemotherapy is the standard of care for patients with advanced BTC in China, its clinical benefits are moderate. In recent years, the approval of targeted therapies and immunotherapies has provided new avenues for the management of advanced BTC. Nonetheless, the increasing number of personalized medicine approaches has created a challenge for clinicians choosing individualized treatment strategies based on tumor characteristics. In this article, we discuss recent progress in implementing precision medicine approaches for advanced BTC in China and examine genomic profiling studies in Chinese patients with advanced BTC. We also discuss the challenges and opportunities of using precision medicine approaches, as well as the importance of considering population-specific factors and tailoring treatment approaches to improve outcomes for patients with BTC. In addition to providing a comprehensive overview of current and emerging precision medicine approaches for the management of advanced BTC in China, this review article will support clinicians outside of China by serving as a reference regarding the role of patient- and population-specific factors in clinical decision-making for patients with this rare malignancy.

Keywords

biliary tract cancer / precision medicine / cholangiocarcinoma / China

References

[1] NCCNClinical Practice Guidelines in Oncology. Biliary Tract Cancers. Version 6. 2024. Available at the website of NCCN

[2] Baria K , De Toni EN , Yu B , Jiang Z , Kabadi SM , Malvezzi M . Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Advances. 2022; 1(4): 618–626

[3] Chen S , Han K , Song Y , Liu S , Li X , Wang S , Li H , Li R , Wang J , He Y , Liu M . Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019. Chin Med J (Engl) 2022; 135(14): 1697–1706

[4] Ellington TD , Momin B , Wilson RJ , Henley SJ , Wu M , Ryerson AB . Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race/ethnicity, and stage at diagnosis: United States, 2013 to 2017. Cancer Epidemiol Biomarkers Prev 2021; 30(9): 1607–1614

[5] Xie W , Yang T , Zuo J , Ma Z , Yu W , Hu Z , Song Z . Chinese and global burdens of gastrointestinal cancers from 1990 to 2019. Front Public Health 2022; 10: 941284

[6] An L , Zheng R , Zhang S , Chen R , Wang S , Sun K , Lu L , Zhang X , Zhao H , Zeng H , Wei W , He J . Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr 2023; 12(1): 45–55

[7] Kang MJ , Lim J , Han SS , Park HM , Kim SW , Lee WJ , Woo SM , Kim TH , Won YJ , Park SJ . Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 2022; 12(1): 10206

[8] Hsu HP , Yang TM , Hsieh YH , Shan YS , Lin PW . Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007; 14(1): 50–60

[9] Jarnagin WR , Ruo L , Little SA , Klimstra D , D’Angelica M , DeMatteo RP , Wagman R , Blumgart LH , Fong Y . Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98(8): 1689–1700

[10] Wang Y , Li J , Xia Y , Gong R , Wang K , Yan Z , Wan X , Liu G , Wu D , Shi L , Lau W , Wu M , Shen F . Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013; 31(9): 1188–1195

[11] Valle J , Wasan H , Palmer DH , Cunningham D , Anthoney A , Maraveyas A , Madhusudan S , Iveson T , Hughes S , Pereira SP , Roughton M , Bridgewater J . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362(14): 1273–1281

[12] Ciombor KK , Goff LW . Advances in the management of biliary tract cancers. Clin Adv Hematol Oncol 2013; 11(1): 28–34

[13] Horgan AM , Amir E , Walter T , Knox JJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30(16): 1934–1940

[14] Zhou J , Tan G , Zhang L , Xie G , Chen W , Zhang X , Liang H . Epidemiology of biliary tract cancer in China: a narrative review. Chin J Cancer Res 2024; 36(5): 474–488

[15] Huang D , Joo H , Song N , Cho S , Kim W , Shin A . Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. Epidemiol Health 2021; 43: e2021011

[16] Andreotti G , Liu E , Gao YT , Safaeian M , Rashid A , Shen MC , Wang BS , Deng J , Han TQ , Zhang BH , Hsing AW . Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation. Cancer Causes Control 2011; 22(9): 1289–1296

[17] Tavolari S , Brandi G . Mutational landscape of cholangiocarcinoma according to different etiologies: a review. Cells 2023; 12(9): 1216

[18] Khan SA , Tavolari S , Brandi G . Cholangiocarcinoma: epidemiology and risk factors. Liver Int 2019; 39(Suppl 1): 19–31

[19] Lundberg Båve A , Bergquist A , Bottai M , Warnqvist A , von Seth E , Nordenvall C . Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int 2021; 15(5): 1174–1182

[20] Aune D , Sen A , Norat T , Riboli E , Folseraas T . Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Sci Rep 2021; 11(1): 10646

[21] Zhou HB , Wang H , Zhou DX , Wang H , Wang Q , Zou SS , Hu HP . Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World J Gastroenterol 2010; 16(7): 881–885

[22] Shebl FM , Andreotti G , Meyer TE , Gao YT , Rashid A , Yu K , Shen MC , Wang BS , Han TQ , Zhang BH , Stanczyk FZ , Hsing AW . Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China. Br J Cancer 2011; 105(9): 1424–1429

[23] Shebl FM , Andreotti G , Rashid A , Gao YT , Yu K , Shen MC , Wang BS , Li Q , Han TQ , Zhang BH , Fraumeni JF Jr , Hsing AW . Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China. Br J Cancer 2010; 103(1): 115–119

[24] Lee SH , Song SY . Recent advancement in diagnosis of biliary tract cancer through pathological and molecular classifications. Cancers (Basel) 2024; 16(9): 1761

[25] Zhang X , Cai Y , Xiong X , Liu A , Zhou R , You Z , Li F , Cheng N . Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. Intractable Rare Dis Res 2022; 11(4): 161–172

[26] Vogel A , Bridgewater J , Edeline J , Kelley RK , Klumpen HJ , Malka D , Primrose JN , Rimassa L , Stenzinger A , Valle JW , Ducreux M . Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34(2): 127–140

[27] Liu T , Li Q , Lin Z , Liu C , Pu W , Zeng S , Lai J , Cai X , Zhang L , Wang S , Chen M , Cao W , Gou H , Zhu Q . A single-arm phase II study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer. Cancer Res Treat 2024; 56(2): 602–615

[28] Yang X , Zhuang L , Dai Y , Qiu H , Yuan X . A prospective, multicenter, phase II trial of albumin-paclitaxel plus cisplatin versus gemcitabine plus cisplatin in first-line treatment of advanced biliary tract tumors (2022 ASCO abstract 4099). J Clin Oncol 2022; 40(16 suppl): 4099

[29] Zhang W , Sun Y , Jiang Z , Qu W , Gong C , Zhou A . Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial. Hepatobiliary Surg Nutr 2023; 12(1): 37–44

[30] Li H , Zhang ZY , Zhou ZQ , Guan J , Tong DN , Zhou GW . Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget 2016; 7(18): 26888–26897

[31] Zou L , Li X , Wu X , Cui J , Cui X , Song X , Ren T , Han X , Zhu Y , Li H , Wu W , Wang X , Gong W , Wang L , Li M , Lau WY , Liu Y . Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer 2021; 21(1): 818

[32] Yang P , Javle M , Pang F , Zhao W , Abdel-Wahab R , Chen X , Meric-Bernstam F , Chen H , Borad MJ , Liu Y , Zou C , Mu S , Xing Y , Wang K , Peng C , Che X . Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr 2019; 8(6): 604–614

[33] Yu H , Xu Y , Gao W , Li M , He J , Deng X , Xing W . Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol 2022; 12: 930611

[34] Lin J , Cao Y , Yang X , Li G , Shi Y , Wang D , Long J , Song Y , Mao J , Xie F , Bai Y , Zhang L , Yang X , Wan X , Wang A , Guan M , Zhao L , Hu K , Pan J , Huo L , Lu X , Mao Y , Sang X , Zhang H , Wang K , Wang X , Zhao H . Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 2021; 11(10): 4585–4598

[35] Guo L , Zhou F , Liu H , Kou X , Zhang H , Chen X , Qiu J . Genomic mutation characteristics and prognosis of biliary tract cancer. Am J Transl Res 2022; 14(7): 4990–5002

[36] Shen J , Kong R , Guo D , Chen S , Han T , Wang M , Lu G , Deng W , Ding R , Bu F . Spectrum of germline pathogenic mutations in 1087 Chinese patients with biliary tract cancer (2022 ESMO abstract 58P). Ann Oncol 2022; 33: S567

[37] Chen C , Wang T , Yang M , Song J , Huang M , Bai Y , Su H . Genomic profiling of blood-derived circulating tumor DNA from patients with advanced biliary tract cancer. Pathol Oncol Res 2021; 27: 1609879

[38] Li G , Pu P , Pan M , Weng X , Qiu S , Li Y , Abbas SJ , Zou L , Liu K , Wang Z , Shao Z , Jiang L , Wu W , Liu Y , Shao R , Liu F , Liu Y . Topological reorganization and functional alteration of distinct genomic components in gallbladder cancer. Front Med 2024; 18(1): 109–127

[39] Xue L , Guo C , Zhang K , Jiang H , Pang F , Dou Y , Liu X , Lin H , Dong X , Zhao S , Yao M , Wang K , Feng Y , Gu W . Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surg Nutr 2019; 8(6): 615–622

[40] Tian W , Hu W , Shi X , Liu P , Ma X , Zhao W , Qu L , Zhang S , Shi W , Liu A , Cao J . Comprehensive genomic profile of cholangiocarcinomas in China. Oncol Lett 2020; 19(4): 3101–3110

[41] Jiang G , Zhang W , Wang T , Ding S , Shi X , Zhang S , Shi W , Liu A , Zheng S . Characteristics of genomic alterations in Chinese cholangiocarcinoma patients. Jpn J Clin Oncol 2020; 50(10): 1117–1125

[42] Xu S , Guo Y , Zeng Y , Song Z , Zhu X , Fan N , Zhang Z , Ren G , Zang Y , Rao W . Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. BMC Cancer 2021; 21(1): 152

[43] Zou S , Li J , Zhou H , Frech C , Jiang X , Chu JS , Zhao X , Li Y , Li Q , Wang H , Hu J , Kong G , Wu M , Ding C , Chen N , Hu H . Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014; 5(1): 5696

[44] Zhou W , Jiang C , Zhan N , Lv X , Fan L , Ninu M . Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: a meta-analysis. J Cancer Res Ther 2018; 14(Suppl 1): S28–S35

[45] Pu X , Zhu L , Li F , Zheng J , Wu H , Fu Y , Chen J , Qi L . Target molecular treatment markers in intrahepatic cholangiocarcinoma based on Chinese population. Pathol Res Pract 2020; 216(9): 153116

[46] Xin HY , Sun RQ , Zou JX , Wang PC , Wang JY , Ye YH , Liu KX , Hu ZQ , Zhou ZJ , Fan J , Zhou J , Zhou SL . Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma. JAMA Netw Open 2023; 6(3): e231476

[47] Zhou SL , Xin HY , Sun RQ , Zhou ZJ , Hu ZQ , Luo CB , Wang PC , Li J , Fan J , Zhou J . Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma. JAMA Surg 2022; 157(1): 59–65

[48] Ruan J , Li Q , Jin Y , Yin J , Ye C , Cheng F , Xu S , Chen R , Liu C , Rong X , Jiang M , Fu W , Zheng D , Chen J , Bao X , Wang H , Sheng J , Zhao P . Multiple-omics analysis reveals a dedifferentiation-immune loop in intrahepatic cholangiocarcinoma. Mol Ther 2025; 33(4): 1803–1824

[49] Shi GM , Huang XY , Wen TF , Song TQ , Kuang M , Mou HB , Bao LQ , Zhao HT , Zhao H , Feng XL , Zhang BX , Peng T , Zhang YB , Li XC , Yu HS , Cao Y , Liu LX , Zhang T , Wang WL , Ran JH , Liu YB , Gong W , Chen MX , Cao L , Luo Y , Wang Y , Zhou H , Yang GH , Fan J , Zhou J . Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study. Cancer Med 2023; 12(4): 4137–4146

[50] Ye J , Qi L , Liang J , Zong K , Liu W , Li R , Feng R , Zhai W . Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. J Cancer 2021; 12(12): 3548–3557

[51] Xu J , Bai Y , Sun H , Bai C , Jia R , Li Y , Zhang W , Liu L , Huang C , Guan M , Zhou J , Su W . A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer 2021; 127(21): 3975–3984

[52] Zhuang X , Xiao YP , Tan LH , Wang LT , Cao Q , Qu GF , Xiao S , Duan H . Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: a meta-analysis of 7 randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 2017; 37(2): 172–178

[53] Wang Y , Wen N , Wang S , Nie G , Tian Y , Lu J , Li B . Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review. BMC Cancer 2023; 23(1): 378

[54] Scott AJ , Sharman R , Shroff RT . Precision medicine in biliary tract cancer. J Clin Oncol 2022; 40(24): 2716–2734

[55] Zhang B , Yao W . Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3, 515 patients. World J Surg Oncol 2022; 20(1): 320

[56] Peng X , Wang X , Hua L , Yang R . Prognostic and clinical value of the systemic immune-inflammation index in biliary tract cancer: a meta-analysis. J Immunol Res 2022; 2022: 6988489

[57] Mao J , Wang D , Long J , Yang X , Lin J , Song Y , Xie F , Xun Z , Wang Y , Wang Y , Li Y , Sun H , Xue J , Song Y , Zuo B , Zhang J , Bian J , Zhang T , Yang X , Zhang L , Sang X , Zhao H . Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021; 9(12): e003334

[58] Yu F , Gong L , Mo Z , Wang W , Wu M , Yang J , Zhang Q , Li L , Yao J , Dong J . Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. Biosci Trends 2019; 13(1): 58–69

[59] Yu J , Zhang X , Huang Q , Tan S , Xiong X , Gou H . Rare DNA mismatch repair-related protein loss in patients with intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma and their response to immunotherapy. Cancer Manag Res 2021; 13: 4283–4290

[60] Song G , Shi Y , Meng L , Ma J , Huang S , Zhang J , Wu Y , Li J , Lin Y , Yang S , Rao D , Cheng Y , Lin J , Ji S , Liu Y , Jiang S , Wang X , Zhang S , Ke A , Wang X , Cao Y , Ji Y , Zhou J , Fan J , Zhang X , Xi R , Gao Q . Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nat Commun 2022; 13(1): 1642

[61] Lin J , Dai Y , Sang C , Song G , Xiang B , Zhang M , Dong L , Xia X , Ma J , Shen X , Ji S , Zhang S , Wang M , Fang H , Zhang X , Wang X , Zhang B , Zhou J , Fan J , Zhou H , Gao D , Gao Q . Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. J Immunother Cancer 2022; 10(7): e004892

[62] Piha-Paul SA , Oh DY , Ueno M , Malka D , Chung HC , Nagrial A , Kelley RK , Ros W , Italiano A , Nakagawa K , Rugo HS , de Braud F , Varga AI , Hansen A , Wang H , Krishnan S , Norwood KG , Doi T . Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020; 147(8): 2190–2198

[63] Mao Y , Wu X , Xu N , Bai Y , Wang D , Chen X , Yin X , Deng Y , Yang J , Zhang J , Tang J , Huang Y , Li J , Xu M , Li N , Mao Y , Gozman A , Xu J . Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158 (2023 ESMO abstract 136P). Ann Oncol 2023; 34: S235

[64] Yang X , Lian B , Li Y , Xue J , Wang Y , Wang Y , Xun Z , Zhang N , Sun H , Long J , Song Z , Lu L , Pan J , Zhao L , Guan M , Yang X , Mao Y , Sang X , Wang K , Zhao HT . Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma (2022 ASCO abstract 4101). J Clin Oncol 2022; 40(16 suppl): 4101

[65] Kelley RK , Ueno M , Yoo C , Finn RS , Furuse J , Ren Z , Yau T , Klümpen HJ , Chan SL , Ozaka M , Verslype C , Bouattour M , Park JO , Barajas O , Pelzer U , Valle JW , Yu L , Malhotra U , Siegel AB , Edeline J , Vogel A; KEYNOTE-966 Investigators . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401(10391): 1853–1865

[66] Yoo C , Finn RS , Klümpen HJ , Kelley RK , Vogel A , Furuse J , Ren Z , Yau T , Chan SL , Ozaka M , Oh SC , Gu S , Park JO , Valle JW , Edeline J , Kamble S , Norquist JM , Yu L , Malhotra U , Ueno M . Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC). J Clin Oncol 2023; 41(16 suppl): 4003

[67] Qin S , Liang T , Gu S , Gou H , Peng C , Pan Y , Song T , Su H , Cao K , Liang H , Ying J , Geng Z , Yu W , Zhao H , Bai Y , Hao CY , Wang W , Li N , Malhotra U , Ren Z . 47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study. Ann Oncol 2024; 35: S230

[68] Oh DY , Ruth He A , Qin S , Chen LT , Okusaka T , Vogel A , Kim JW , Suksombooncharoen T , Ah Lee M , Kitano M , Burris H , Bouattour M , Tanasanvimon S , McNamara MG , Zaucha R , Avallone A , Tan B , Cundom J , Lee CK , Takahashi H , Ikeda M , Chen JS , Wang J , Makowsky M , Rokutanda N , He P , Kurland JF , Cohen G , Valle JW . Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1(8): EVIDoa2200015

[69] Oh DY , He AR , Qin S , Chen LT , Okusaka T , Vogel A , Kim JW , Lee T , Lee MA , Kitano M , Burris HA , Bouattour M , Tanasanvimon S , Zaucha RE , Avallone A , Cundom JE , Rokutanda N , Żotkiewicz M , Cohen G , Valle JW . 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 2022; 33: S1462–S1463

[70] Qin S , Cai JQ , Li E , Xing B , Zhao L , Dai C , Li J , Shen Y , Chen Z , Liu L , Lu Z , Zang A , Bai Y , Liang H , Liang J , Liu X , Wang J , Chen MH , Miao R , Qu X . Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study (2023 ESMO abstract 98P). Ann Oncol 2023; 34: S216–S7

[71] Hui Z , Yu W , Fuzhen W , Liping S , Guomin Z , Jianhua L , Feng W , Ning M , Jian L , Guowei D , Tongtong M , Lin T , Shuang Z , Mingshuang L , Yuan L , Xiaoqi W , Qianqian L , Qian Z , Dan W , Tingting Y , Qiudong S , Miao W , Li L , Qian H , Yixing L , Yi L , Shaodong Y , Zhijie A , Rodewald LE , Jidong J , Huaqing W , Wenzhou Y , Zhongfu L , Qun L , Zijian F , Zundong Y , Yu W . New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac. 2024; 51: 101193

[72] Chen X , Qin S , Gu S , Ren Z , Chen Z , Xiong J , Liu Y , Meng Z , Zhang X , Wang L , Zhang X , Zou J . Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int J Cancer 2021; 149(11): 1944–1954

[73] Qin S , Chen Z , Liu Y , Xiong J , Ren Z , Meng Z , Gu SZ , Wang L , Zou J . A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clin Oncol 2019; 37(15 suppl): 4074

[74] Chen X , Wu X , Wu H , Gu Y , Shao Y , Shao Q , Zhu F , Li X , Qian X , Hu J , Zhao F , Mao W , Sun J , Wang J , Han G , Li C , Xia Y , Seesaha PK , Zhu D , Li H , Zhang J , Wang G , Wang X , Li X , Shu Y . Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer 2020; 8(2): e001240

[75] Yuan Z-g , Zeng T-m , Tao C-j , Yang G , Xu H-m , Wei W . . Biomarker analysis of first-line sintilimab plus gemcitabine and cisplatin in patients with advanced biliary tract cancers: results from a phase II study (2022 ASCO abstract e16189). J ClinOncol 2022; 40(16_suppl): e16189

[76] Zhao S , Guo XG , Zhang D , Zhou G , Song P , Yang J , Zhang Y , Li P , Hu Y , Wang P . First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer. J Gastroenterol Hepatol 2021; 36(12): 3541–3547

[77] Gou M , Zhang Y , Liu T , Si H , Wang Z , Yan H , Qian N , Dai G . PD-1 inhibitors could improve the efficacy of chemotherapy as first-line treatment in biliary tract cancers: a propensity score matching based analysis. Front Oncol 2021; 11: 648068

[78] Tan S , Yu J , Huang Q , Zhou N , Gou H . PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: a retrospective analysis of a case series. Front Oncol 2022; 12: 1006075

[79] Sun D , Ma J , Wang J , Han C , Qian Y , Chen G , Li X , Zhang J , Cui P , Du W , Wu Z , Chen S , Zheng X , Yue Z , Song J , Gao C , Zhao X , Cai S , Hu Y . Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother 2019; 68(9): 1527–1535

[80] Fan J , Zhou J , Shi G , Huang X , Guo X , Lu J , Liang F , Chen Y , Wu D , Ji Y , Hou Y , Meng X , Tang Z , Huang X , Ye Q , Qiu S , Gao Q , Shi Y , Sun H , Li H . A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy (2023 ESMO abstract 105P). Ann Oncol 2023; 34: S221

[81] Wang X , Fu S , Zheng K , Cao G , Xu L , Yang R , Zhu X , Liu P , Gao S , Xu H , Guo J , Chen H , Wang K , Li J , Zhou J , Zhang X , Hao C , Xing B , Shen L . A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report (2022 ESMO abstract 60P). Ann Oncol 2022; 33: S568

[82] Guo Y , Feng K , Liu Y , Wu Z , Dai H , Yang Q , Wang Y , Jia H , Han W . Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res 2018; 24(6): 1277–1286

[83] Leem G , Jang SI , Cho JH , Jo JH , Lee HS , Chung MJ , Park JY , Bang S , Yoo DK , Cheon HC , Kim JE , Lim KP , Jung IH , Im JM , Chung YY , Park SW . Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1/2a trial. Cancers (Basel) 2022; 14(17): 4229

[84] Lu Z , Chang L , Zhou J , Ji Y , Sun M , Wen Q , Gao SG , Ma XL , Zhong D , Guo Q , Xiao S , Wang H , Zhu H , Zhu Y , Shen L . BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC). Ann Oncol 2024; 35(Suppl 2): S233

[85] Zhang Q , Liu X , Wei S , Zhang L , Tian Y , Gao Z , Jin M , Yan S . Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study. Front Oncol 2021; 11: 751391

[86] Wu Z , Zhu X , Zhong X , Wang Y , Zheng Y , Han W , Pan H , Yao J . Efficacy and safety of PD-1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: a multicenter retrospective study. Exp Ther Med 2023; 26(1): 352

[87] Shen J , Kong W , Zhu S , Liu B . A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer (2022 ASCO abstract 4077). J Clin Oncol 2022; 40(16 suppl): 4077

[88] Villanueva L , Lwin Z , Chung HC , Gomez-Roca C , Longo F , Yanez E , Senellart H , Doherty M , García-Corbacho J , Hendifar AE , Maurice-Dror C , Gill SS , Kim TW , Heudobler D , Penel N , Ghori R , Kubiak P , Jin F , Norwood KG , Graham D . Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. J Clin Oncol 2021; 39(3 suppl): 321

[89] O’Bryan J , Yin C , Weinberg BA , Noel MS , Mukherji R , Kulasekaran M , Agarwal S , Kupfer G , Wang H , Hartley ML , Marshall J , He AR . Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer. J Clin Oncol 2023; 41(16 suppl): 4087

[90] Wang D , Yang X , Long J , Lin J , Mao J , Xie F , Wang Y , Wang Y , Xun Z , Bai Y , Yang X , Guan M , Pan J , Seery S , Sang X , Zhao H . The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol 2021; 11: 646979

[91] Shi C , Li Y , Yang C , Qiao L , Tang L , Zheng Y , Chen X , Qian Y , Yang J , Wu D , Xie F . Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China. Front Immunol 2022; 13: 946861

[92] Lin J , Yang X , Long J , Zhao S , Mao J , Wang D , Bai Y , Bian J , Zhang L , Yang X , Wang A , Xie F , Shi W , Yang H , Pan J , Hu K , Guan M , Zhao L , Huo L , Mao Y , Sang X , Wang K , Zhao H . Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020; 9(4): 414–424

[93] Zhu S , Liu C , Dong Y , Shao J , Liu B , Shen J . A retrospective study of lenvatinib monotherapy or combined with programmed cell death protein 1 antibody in the treatment of patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma in China. Front Oncol 2021; 11: 788635

[94] Chao J , Wang S , Wang H , Zhang N , Wang Y , Yang X , Zhu C , Ning C , Zhang X , Xue J , Zhang L , Piao M , Wang M , Yang X , Lu L , Zhao H . Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunol Immunother 2023; 72(11): 3717–3726

[95] Jingjing L , Xu Q , Xu X , Cong L , Ying J . A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC. J Clin Oncol 2023; 41(16 suppl): 4015

[96] Jingjing L , Qi X , Wei Q , Han Z , Cong L , Zhang F , Ying J . A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC (2022 ASCO abstract 4100). J Clin Oncol 2022; 40(16 suppl): 4100

[97] Shi GM , Huang XY , Wu D , Sun HC , Liang F , Ji Y , Chen Y , Yang GH , Lu JC , Meng XL , Wang XY , Sun L , Ge NL , Huang XW , Qiu SJ , Yang XR , Gao Q , He YF , Xu Y , Sun J , Ren ZG , Fan J , Zhou J . Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 2023; 8(1): 106

[98] Li H . A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers (2022 ESMO abstract 65P). Ann Oncol 2022; 33: S570

[99] Guo J , Zhou Q , Zhou M , Dai H , Li L , Qiu Y , Mao L , Liu B , Shen J . Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: a retrospective study. Cancer Med 2023; 12(22): 20699–20711

[100] Zeng J , Ma J , Zeng Z , Yang L , Jiang Y , Mo N , Ma F , Liu C , Li R , Tang J , Qin S , Jiang H . A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma. J Gastrointest Oncol 2023; 14(2): 758–767

[101] Zhu C , Li H , Yang X , Wang S , Wang Y , Zhang N , Wang Y , Xue J , Zhang L , Ning C , Yang X , Xun Z , Chao J , Long J , Sang X , Zhu Z , Zhao H . Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study. Cancer Immunol Immunother 2023; 72(9): 2949–2960

[102] Zhu C , Xue J , Wang Y , Wang S , Zhang N , Wang Y , Zhang L , Yang X , Long J , Yang X , Sang X , Zhao H . Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol 2023; 14: 1109292

[103] Ye Z , Zhang Y , Chen J , Wang X , Hong Y , Zhao Q . First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: a retrospective real-world study. Int Immunopharmacol 2023; 120: 110344

[104] Wang K , Liu ZH , Yu HM , Cheng YQ , Xiang YJ , Zhong JY , Ni QZ , Zhou LP , Liang C , Zhou HK , Pan WW , Guo WX , Shi J , Cheng SQ . Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Therap Adv Gastroenterol 2023; 16: 17562848231160630

[105] Zhang N , Yu BR , Wang YX , Zhao YM , Zhou JM , Wang M , Wang LR , Lin ZH , Zhang T , Wang L . Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis 2022; 23(8–9): 535–545

[106] Wang Y , Xun Z , Yang X , Wang Y , Wang S , Xue J , Zhang N , Yang X , Lu Z , Zhou J , Zhou K , Sang X , Zhao H . Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer. Am J Cancer Res 2023; 13(3): 1026–1037

[107] Wei Z , Wang Y , Wu B , Liu Y , Wang Y , Ren Z , Yang X , Chen Q , Zhang Y . Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma. Front Immunol 2023; 14: 1235724

[108] Zhang T , Yang X , Yang X , Zheng K , Wang Y , Wang Y , Sang X , Lu X , Xu Y , Wang X , Zhao H . Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study. Am J Cancer Res 2022; 12(7): 3455–3463

[109] Zheng Z , Wang J , Wu T , He M , Pan Y , Wang J , Chen J , Hu D , Xu L , Zhang Y , Chen M , Zhou Z . Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. Int J Surg 2025; 111(1): 1552–1557

[110] Cercek A , Boerner T , Tan BR , Chou JF , Gonen M , Boucher TM , Hauser HF , Do RKG , Lowery MA , Harding JJ , Varghese AM , Reidy-Lagunes D , Saltz L , Schultz N , Kingham TP , D’Angelica MI , DeMatteo RP , Drebin JA , Allen PJ , Balachandran VP , Lim KH , Sanchez-Vega F , Vachharajani N , Majella Doyle MB , Fields RC , Hawkins WG , Strasberg SM , Chapman WC , Diaz LA Jr , Kemeny NE , Jarnagin WR . Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020; 6(1): 60–67

[111] Wang Y , Zhang N , Xue J , Zhu C , Wang Y , Zhang L , Yang X , Wang H , Wang S , Chao J , Yang X , Zhao H . Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC. Front Immunol 2023; 14: 1084843

[112] Chen W , Xu D , Liu Q , Wu Y , Wang Y , Yang J . Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. Biomed Pharmacother 2023; 162: 114697

[113] Xu X , Cheng S , Ding C , Lv Z , Chen D , Wu J , Zheng S . Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method. Mol Med Rep 2015; 11(3): 2191–2198

[114] Helmink BA , Roland CL , Kiernan CM , Wargo JA . Toxicity of immune checkpoint inhibitors: considerations for the surgeon. Ann Surg Oncol 2020; 27(5): 1533–1545

[115] Du R , Wang X , Ma L , Larcher LM , Tang H , Zhou H , Chen C , Wang T . Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer 2021; 21(1): 206

[116] Hsing AW , Gao YT , McGlynn KA , Niwa S , Zhang M , Han TQ , Wang BS , Chen J , Sakoda LC , Shen MC , Zhang BH , Deng J , Rashid A . Biliary tract cancer and stones in relation to chronic liver conditions: a population-based study in Shanghai, China. Int J Cancer 2007; 120(9): 1981–1985

[117] Wu Q , He XD , Yu L , Liu W , Tao LY . The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev 2012; 13(5): 1963–1969

[118] Conde J , Oliva N , Zhang Y , Artzi N . Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater 2016; 15(10): 1128–1138

[119] Qu WF , Ding ZB , Qu XD , Tang Z , Zhu GQ , Fu XT , Zhang ZH , Zhang X , Huang A , Tang M , Tian MX , Jiang XF , Huang R , Tao CY , Fang Y , Gao J , Wu XL , Zhou J , Fan J , Liu WR , Shi YH . Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open 2022; 6(5): zrac114

[120] Camidge DR , Barlesi F , Goldman JW , Morgensztern D , Heist RS , Vokes EE , Spira AI , Angevin E , Su WC , Hong DS , Strickler JH , Motwani M , Sun Z , Parikh A , Noon E , Wu J , Kelly K . Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. J Clin Oncol 2019; 37(15 suppl): 3011

[121] Han HS , Alemany CA , Brown-Glaberman UA , Pluard TJ , Sinha R , Sterrenberg D , Albain KS , Basho RK , Biggs D , Boni V , Diab S , Tsai ML , Tkaczuk KH , Wang Y , Wang Z , Meisel JL . SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (ASCO abstract TPS1110). J Clin Oncol 2019; 37(15 suppl): TPS1110

[122] Demir T , Moloney C , Mahalingam D . Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers. Crit Rev Oncol Hematol 2024; 199: 104388

[123] Mayr C , Kiesslich T , Modest DP , Stintzing S , Ocker M , Neureiter D . Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned. Expert Opin Investig Drugs 2022; 31(2): 221–233

[124] Toledo B , Deiana C , Scianò F , Brandi G , Marchal JA , Perán M , Giovannetti E . Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Rev Clin Pharmacol 2024; 17(4): 323–347

[125] Bai X , Chen J , Zhang W , Zhou S , Dong L , Huang J , He X . YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m⁶A-dependent DAPK3 degradation. Cancer Sci 2023; 114(11): 4299–4313

[126] Xu S , Jiang C , Lin R , Wang X , Hu X , Chen W , Chen X , Chen T . Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. J Exp Clin Cancer Res 2021; 40(1): 373

[127] Yang L , Wang H , Guo M , He M , Zhang W , Zhan M , Liu Y . ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer. Cell Oncol (Dordr) 2023; 46(4): 1085–1095

[128] Shi X , Hu Z , Bai S , Zong C , Xue H , Li Y , Li F , Chen L , Xuan J , Xia Y , Wei L , Shen F , Wang K . YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis. J Gene Med 2024; 26(5): e3689

[129] Song F , Wang CG , Wang TL , Tao YC , Mao JZ , Hu CW , Zhang Y , Tang PJ , Lu CL , Qing HL , Han L , Chen Z . Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through Saikosaponin-a mediated modulation of the p-AKT/BCL-6/ABCA1 axis. Phytomedicine 2024; 133: 155944

[130] Yuan F , Zhou H , Liu C , Wang Y , Quan J , Liu J , Li H , von Itzstein M , Yu X . Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway. Cancer Gene Ther 2024; 31(6): 904–916

[131] Huang T , Cao H , Liu C , Sun X , Dai S , Liu L , Wang Y , Guo C , Wang X , Gao Y , Tang W , Xia Y . MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell Death Dis 2024; 15(6): 411

[132] He S , Shen J , Sun X , Liu L , Dong J . A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 2014; 26(4): 243–247

[133] Chen JS , Hsu C , Chiang NJ , Tsai CS , Tsou HH , Huang SF , Bai LY , Chang IC , Shiah HS , Ho CL , Yen CJ , Lee KD , Chiu CF , Rau KM , Yu MS , Yang Y , Hsieh RK , Chang JY , Shan YS , Chao Y , Chen LT , Shen WC , Hsu HC , Hsu CH , Shen YC , Wang TE , Li CP , Chen MH , Kao WY , Chang PY , Wu CC , Teng CL , Lu CH , Lin SJ , Wang BW , Chen YY , Chin YH , Chung TR , Yu WL , Lee MH , Lin LF , Lin PC , Wu YL , Wang HL , Lu LJ , Chen SY , Wu CC , Wei TC . A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol 2015; 26(5): 943–949

[134] Chen X , Wang D , Liu J , Qiu J , Zhou J , Ying J , Shi Y , Wang Z , Lou H , Cui J , Zhang J , Liu Y , Zhao F , Pan L , Zhao J , Zhu D , Chen S , Li X , Li X , Zhu L , Shao Y , Shu Y . Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer 2021; 9(11): e003214

[135] Li W , Wang Y , Yu Y , Li Q , Wang Y , Zhang C , Xu X , Guo X , Cui Y , Hao Q , Huang L , Liu H , Liu T . Toripalimab combined with gemcitabine and S-1 in the first-line treatment of advanced biliary tract cancer (2022 ASCO abstract 4081). J Clin Oncol 2022; 40(16 suppl): 4081

[136] Tsurutani J , Iwata H , Krop I , Janne PA , Doi T , Takahashi S , Park H , Redfern C , Tamura K , Wise-Draper TM , Saito K , Sugihara M , Singh J , Jikoh T , Gallant G , Li BT . Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 2020; 10(5): 688–701

[137] Kim SB , Meric-Bernstam F , Kalyan A , Babich A , Liu R , Tanigawa T , Sommer A , Osada M , Reetz F , Laurent D , Wittemer-Rump S , Berlin J . First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol 2019; 14(5): 591–601

RIGHTS & PERMISSIONS

Merck & Co., Inc., Rahway, NJ, USA and its affiliates and Zhen Huang, Wen Zhang, Yongkun Sun, Dong Yan, Hong Zhao